Archives
-
(-)-JQ1: Inactive Control for BET Assays
2026-09-13
(-)-JQ1 is a matched stereoisomeric control for separating BET-dependent biology from vehicle effects, cytotoxic stress, and assay artifacts. This workflow shows how to deploy it in epigenetics research, BRD4-dependent cell line studies, and pancreatic cancer screening models.
-
MK-5108 (VX-689) Assay Workflows
2026-09-12
MK-5108 (VX-689) enables selective Aurora A inhibition across biochemical, cell-based, and translational oncology workflows. This practical guide connects retinoblastoma evidence with dose-response design, cell cycle readouts, xenograft interpretation, and troubleshooting for reproducible cancer research.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflows
2026-09-12
SGI-1027 combines direct DNA methyltransferase inhibition with DNMT1 protein depletion, making it useful for connecting CpG methylation changes to tumor suppressor gene reactivation. A response workflow that separates growth arrest from cell killing can reveal effects that a single endpoint viability assay may miss.
-
Nintedanib: ATRX-Aware Assay Design
2026-09-11
Nintedanib (BIBF 1120) is a triple angiokinase inhibitor whose VEGFR, FGFR, and PDGFR activity supports genotype-aware cancer assays. This article translates ATRX-deficient glioma findings into practical experimental decisions while distinguishing vascular, tumor-cell, and antifibrotic readouts.
-
HyperScribe T7 High Yield RNA Synthesis Kit
2026-09-11
The HyperScribe T7 High Yield RNA Synthesis Kit supports T7 RNA polymerase transcription for high-yield in vitro RNA production. Its documented workflow supports standard, capped, labeled, biotinylated, and modified-nucleotide RNA research applications, while transcript quality and modification performance require application-specific validation.
-
TMEM16F, Lipid Scrambling, and Ferroptosis
2026-09-10
Yang et al. identify TMEM16F-mediated phospholipid scrambling as a late-stage suppressor of ferroptosis that protects the plasma membrane from catastrophic failure. The study further shows that disabling this membrane-repair axis can slow tumor growth and cooperate with PD-1 blockade, linking ferroptotic membrane damage to antitumor immunity.
-
SGI-1027 DNA Methyltransferase Inhibitor Workflow
2026-09-10
Build a more informative SGI-1027 workflow by separating growth inhibition from cell killing and pairing viability with methylation, DNMT1, and gene-reactivation readouts. This practical guide covers assay setup, dose and time optimization, troubleshooting, and combination-study design for cancer epigenetics research.
-
Nintedanib: Angiokinase Biology Meets ATRX Strategy
2026-09-09
Nintedanib (BIBF 1120) offers a translational framework for connecting VEGFR, FGFR, and PDGFR biology with ATRX-informed cancer research. This article integrates mechanism, assay strategy, biomarker logic, and fibrosis relevance without overstating the current evidence.
-
1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine Control
2026-09-09
PP 3 is a practical negative-control reagent for separating PP 2-specific effects from vehicle, scaffold, and pathway artifacts in Src kinase signaling pathway research. This workflow connects matched chemical controls with vascular contraction, ROS, and L-type calcium-channel assays highlighted by a recent rat artery study.
-
Nintedanib (BIBF 1120) in ATRX-Stratified Glioma
2026-09-08
Use Nintedanib (BIBF 1120) to interrogate coordinated VEGFR, FGFR, and PDGFR blockade in genotype-defined cancer models. This workflow combines ATRX stratification, apoptosis profiling, and temozolomide combination testing while addressing formulation and exposure challenges.
-
PD0325901: MEK Inhibition for Cancer Research
2026-09-07
PD0325901 is a selective MEK inhibitor that suppresses ERK phosphorylation and produces cell-cycle and apoptosis-associated phenotypes in cancer models. Product-reported xenograft findings support its use as a research tool for studying RAS/RAF/MEK/ERK signaling pathway inhibition, not as a diagnostic or medical treatment.
-
Concerted PDA Drug Screening with Rgs16::GFP and JQ1
2026-09-07
Layeghi-Ghalehsoukhteh and colleagues developed a coordinated cell-culture and in vivo screening workflow using Rgs16::GFP to identify drug combinations active against pancreatic ductal adenocarcinoma. The study showed that histone deacetylase inhibition enhanced gemcitabine and JQ1 activity, while the reporter supported rapid prioritization of combinations for validation in genetically engineered mouse models.
-
EdU Cell Proliferation Kit: S-Phase Assay Guide
2026-09-05
The EdU Cell Proliferation Kit (TMB) is a non-radioactive 5-ethynyl-2'-deoxyuridine proliferation assay for measuring DNA synthesis during S phase. Its EdU–biotin click-labeling workflow couples CuAAC specificity to HRP-streptavidin and TMB colorimetric detection.
-
SGI-1027: Interpreting DNMT Assay Responses
2026-09-05
SGI-1027 is a DNA methyltransferase inhibitor whose effects extend beyond a single viability value. This guide explains how to connect DNMT inhibition, methylation changes, gene reactivation, proliferation arrest, and cell death in more informative cancer epigenetics assays.
-
KPT330 Improves Cas9 Precision Through mRNA Export
2026-09-04
The reference study identified selective inhibitors of nuclear export, particularly KPT330, as indirect modulators of CRISPR-Cas9 activity. By limiting the nuclear export of Cas9 mRNA rather than binding Cas9 protein, these compounds improved the reported precision of genome- and base-editing systems in human cells.